文献速递神经免疫

墨西哥多发性硬化的疾病负担

The Burden of Multiple Sclerosis in Mexico.
PubMed 文献 · Neurology · 2025-02-05

本研究基于2021年全球疾病负担(GBD)数据,分析墨西哥1990至2021年多发性硬化的患病、发病、伤残调整生命年(DALYs)、伤残损失健康生命年(YLDs)和早逝损失生命年(YLLs),并探讨与社会人口指数(SDI)的关系。2021年墨西哥约有18,016例多发性硬化患者,年龄标化患病率为每10万居民13.10例;北部地区健康结局优于预期,中部和南部DALYs高于预期。

要点

  • 2021年墨西哥多发性硬化年龄标化患病率为每10万居民13.10例(95% UI 10.91-15.50)。
  • 2021年多发性硬化年龄标化DALYs为每10万居民13.05,其中YLLs 9.47、YLDs 3.56。
  • 北部地区健康结局优于预期,中部和南部观察到的DALYs高于预期。

核心结论

  • 墨西哥多发性硬化疾病负担存在显著地区差异,北部健康结局优于预期,中部和南部疾病负担高于预期。
  • 这些差异提示社会经济因素和卫生服务可及性对多发性硬化结局有显著影响。
  • 作者认为加强数据收集和综合卫生保健策略对有效应对墨西哥日益增长的多发性硬化负担至关重要。

研究设计与样本

  • 基于2021年全球疾病负担(GBD)研究数据,采用标准GBD方法分析墨西哥1990至2021年多发性硬化的流行病学。
  • 关键指标包括患病率、DALYs、YLDs和YLLs,均按年龄标化。
  • 采用Pearson相关和线性回归评估社会人口指数(SDI)与多发性硬化患病率的关系。
  • 应用局部加权回归(LOESS)模型比较基于SDI的观察DALY率与预期DALY率,识别地区差异。

主要发现

  • 2021年墨西哥估计有18,016例多发性硬化患者(95% UI 14,993-21,337)。
  • 2021年年龄标化患病率为每10万居民13.10例(95% UI 10.91-15.50),发病率为每10万居民0.65例(95% UI 0.55-0.75)。
  • 2021年多发性硬化总DALYs为17,947(95% UI 14,458-20,542),即年龄标化DALYs每10万居民13.05。
  • YLLs为每10万居民9.47(95% UI 8.24-10.85),YLDs为每10万居民3.56(95% UI 2.45-4.77)。
  • LOESS模型显示显著地区差异:北部墨西哥健康结局优于预期,中部和南部墨西哥观察到的DALYs高于预期。

关键数值与推荐

  • 2021年墨西哥多发性硬化年龄标化患病率为每10万居民13.10例(95% UI 10.91-15.50)。
  • 2021年多发性硬化发病率为每10万居民0.65例(95% UI 0.55-0.75)。
  • 2021年多发性硬化年龄标化DALYs为每10万居民13.05,其中YLLs每10万居民9.47(95% UI 8.24-10.85)、YLDs每10万居民3.56(95% UI 2.45-4.77)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 研究局限性包括依赖医院记录。
  • 较不发达地区可能存在诊断不足。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVES: Multiple sclerosis (MS) is a CNS disease causing significant disability, mainly in young and middle-aged individuals. Despite extensive global research, Mexico lacks comprehensive epidemiologic data on MS, complicating effective health care planning and intervention. This study analyzes the epidemiology of MS in Mexico using data from the Global Burden of Disease (GBD) study. It focuses on prevalence, incidence, disability-adjusted life years (DALYs), years lived with disability (YLDs), and years of life lost (YLLs) from 1990 to 2021. In addition, it examines the relationship between the sociodemographic index (SDI) and MS burden across Mexican states. METHODS: Data were sourced from the GBD 2021 and analyzed using standard GBD methodologies. Key metrics included prevalence, DALYs, YLDs, and YLLs, standardized by age. Pearson correlation and linear regression were used to evaluate the association between SDI and MS prevalence. A locally weighted regression (LOESS) model was applied to compare observed and expected DALY rates based on SDI, identifying regional disparities in MS burden. RESULTS: In 2021, an estimated 18,016 individuals (95% uncertainty interval [UI] 14,993-21,337) lived with MS in Mexico, with an age-standardized prevalence of 13.10 per 100,000 inhabitants (95% UI 10.91-15.50). The incidence rate was 0.65 per 100,000 inhabitants (95% UI 0.55-0.75). Total DALYs for MS in 2021 were 17,947 (95% UI 14,458-20,542), comprising 13.05 age-standardized DALYs per 100,000 inhabitants. YLLs accounted for 9.47 per 100,000 inhabitants (95% UI 8.24-10.85) and YLDs for 3.56 (95% UI 2.45-4.77). The LOESS model revealed significant regional discrepancies, with Northern Mexico exhibiting better-than-expected health outcomes while Central and Southern Mexico displaying higher observed DALYs than expected. DISCUSSION: The findings highlight substantial regional disparities in the MS burden across Mexico. Northern Mexico showed better-than-expected health outcomes while Central and Southern Mexico exhibited higher disease burdens than anticipated. These discrepancies suggest that socioeconomic factors and health care accessibility significantly affect MS outcomes. The study's limitations include reliance on hospital records and potential underdiagnosis in less developed regions. Enhanced data collection and comprehensive health care strategies are essential to effectively address the growing MS burden in Mexico.

来源:Neurology,查看原文。版权归原作者所有。

引用

  1. Gómez-Figueroa E, Moreno-Bernardino CJ, De Alba-Sánchez AM, et al. The Burden of Multiple Sclerosis in Mexico. Neurology. 2025. PMID: 39908467. doi:10.1212/WNL.0000000000213343

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。